A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study
Clinical Trial Information
Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer
EFS, where events include disease progression or relapse, second malignancy, or death [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ] Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle.
Ages Eligible for Study: 2 Years to 18 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No